Table 4.

Key results of the pivotal tazemetostat study30 

Patient cohortNumber of patientsORR (by IRC)CRRPFS, median (mo)DOR, median (mo)Treatment-related adverse events (any grade) in ≥10% of patientsTreatment-related adverse events (grade 3-4) in ≥2% of patients
EZH2 mutated 45 69% 13% 14 11 Nausea (19%) Anemia (2%) 
EZH2 wild-type 54 35% 4% 11 13 
  • Diarrhea (12%)

  • Alopecia (14%)

  • Asthenia (14%)

  • Fatigue (12%)

 
  • Thrombocytopenia (3%)

  • Leukopenia (3%)

 
Patient cohortNumber of patientsORR (by IRC)CRRPFS, median (mo)DOR, median (mo)Treatment-related adverse events (any grade) in ≥10% of patientsTreatment-related adverse events (grade 3-4) in ≥2% of patients
EZH2 mutated 45 69% 13% 14 11 Nausea (19%) Anemia (2%) 
EZH2 wild-type 54 35% 4% 11 13 
  • Diarrhea (12%)

  • Alopecia (14%)

  • Asthenia (14%)

  • Fatigue (12%)

 
  • Thrombocytopenia (3%)

  • Leukopenia (3%)

 

CRR, complete response rate; DOR, duration of response; IRC, independent review committee; ORR, overall response rate.

Close Modal

or Create an Account

Close Modal
Close Modal